![Meg Wood](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Meg Wood
Direktor/Vorstandsmitglied bei
Aronora, Inc.
Profil
Meg Wood is a venture capital business development executive with experience creating emerging growth strategies for portfolio investment.
As the Managing Director of NYBC Ventures, Meg oversees deal execution and management.
Board Observer for NYBC Ventures portfolio companies Catena Biosciences and KaloCyte.
Previously, Meg built and managed a $50 million fund for scientific research and innovation for a rare disease as the Vice President of Business Development at CD Ventures.
She has deep experience deploying investment capital for mission-oriented fund structures.
Prior to her role at CD Ventures, she held positions at MPM Capital, Tufts Medical Center and Boston Medical Center.
She received Master’s degrees in social work and public health from Boston University and her BA from the College of Charleston.
Aktive Positionen von Meg Wood
| Unternehmen | Position | Beginn |
|---|---|---|
Nybc Ventures
 Nybc Ventures Investment ManagersFinance NYBC Ventures invests in companies located in the United States. The firm targets companies operating in the fields of blood & cellular therapies and related technologies. It provides financing for early stage capital requirements. | Private Equity Investor | 01.04.2022 |
New York Blood Center, Inc.
 New York Blood Center, Inc. Medical/Nursing ServicesHealth Services Operates as blood collection and distribution organization | Private Equity Investor | 01.09.2021 |
Aronora, Inc.
 Aronora, Inc. Pharmaceuticals: MajorHealth Technology Engages in development of biologic drugs | Direktor/Vorstandsmitglied | 01.07.2023 |
Rarebase, PBC
 Rarebase, PBC BiotechnologyHealth Technology Provides drug discovery services | Berater | 01.08.2021 |
Thymmune Therapeutics
 Thymmune Therapeutics BiotechnologyHealth Technology Operates as a preclinical stage biotechnology company that develops regenerative thymic cell therapies for the treatment of posttransplant organ tolerance, immunodeficiencies and autoimmune diseases | Direktor/Vorstandsmitglied | 01.03.2023 |
KaloCyte, Inc.
 KaloCyte, Inc. BiotechnologyHealth Technology Develops red blood cell substitutes used for trauma care related treatments | Direktor/Vorstandsmitglied | 01.05.2022 |
Ehemalige bekannte Positionen von Meg Wood
| Unternehmen | Position | Ende |
|---|---|---|
CureDuchenne Ventures LLC
 CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures seeks investment opportunities located in the United States. The firm targets companies operating in the fields of health technology companies. It provides financing for early-stage capital requirements. | Private Equity Investor | 01.08.2021 |
MPM BioImpact LLC
 MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Private Equity Investor | 01.06.2016 |
Catena Biosciences, Inc.
 Catena Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops therapeutics through protein conjugation technologies | Direktor/Vorstandsmitglied | - |
Ausbildung von Meg Wood
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
75
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
New York Blood Center, Inc.
New York Blood Center, Inc. Medical/Nursing ServicesHealth Services Operates as blood collection and distribution organization | Health Services |
MPM BioImpact LLC
MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
College of Charleston
 College of Charleston Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CureDuchenne Ventures LLC
CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures seeks investment opportunities located in the United States. The firm targets companies operating in the fields of health technology companies. It provides financing for early-stage capital requirements. | Finance |
KaloCyte, Inc.
KaloCyte, Inc. BiotechnologyHealth Technology Develops red blood cell substitutes used for trauma care related treatments | Health Technology |
Aronora, Inc.
Aronora, Inc. Pharmaceuticals: MajorHealth Technology Engages in development of biologic drugs | Health Technology |
Rarebase, PBC
Rarebase, PBC BiotechnologyHealth Technology Provides drug discovery services | Health Technology |
Catena Biosciences, Inc.
Catena Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops therapeutics through protein conjugation technologies | Health Technology |
Thymmune Therapeutics
Thymmune Therapeutics BiotechnologyHealth Technology Operates as a preclinical stage biotechnology company that develops regenerative thymic cell therapies for the treatment of posttransplant organ tolerance, immunodeficiencies and autoimmune diseases | Health Technology |
Nybc Ventures
Nybc Ventures Investment ManagersFinance NYBC Ventures invests in companies located in the United States. The firm targets companies operating in the fields of blood & cellular therapies and related technologies. It provides financing for early stage capital requirements. | Finance |
